FDA's RUO Draft Guidance Will Harm Labs and Dx Makers Alike, AMP Says

If reagents or other test components have been used for years safely and efficaciously, why change the rules mid-play and risk blunting test makers and clinical labs, not to mention patient safety, which is FDA's chief mandate?

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.